Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
A New Vision for Radiation Therapy The MRIdian™ system gives physicians more control over the delivery of their radiation therapy prescriptions. With other radiotherapy technologies, imaging can only take place before or after the treatment; while the beam is on, clinicians cannot see exactly where the therapy target is located inside a patient’s body. Even with precise treatment plans, the motion of internal soft tissues can cause a tumor and nearby organs to be in different positions when the treatment actually occurs. The MRIdian system was designed to solve this problem. Using a patented combination of magnetic resonance imaging (MRI) and radiation therapy delivery technologies, the MRIdian system provides continuous softtissue imaging during treatment. Clinicians can see the target, monitor the radiation dose, and adapt to changes in the patient’s anatomy—all in real time. If the patient moves during treatment—simply taking a breath or swallowing can be enough to shift internal organs—clinicians must be able to refine the target so the tumor will get an optimized dose. The ViewRay solution | With the MRIdian system, clinicians can see the tumor, refine the target, and adapt to changes in the patient’s anatomy—while the treatment is in progress. The MRIdian system assures that the treatment is delivered only when the target is safely within parameters set by the physician—parameters based on the exact position of the tumor at the moment of treatment. Real-time MRI gives clinicians a clear view of the patient’s anatomy throughout the treatment. Applications Management Nearly two-thirds of all cancer patients receive radiation therapy during their illness. The MRIdian system, with MRI capabilities, is intended to provide stereotactic radiosurgery and precision radiation therapy for lesions, tumors, and conditions anywhere in the body where radiation treatment is indicated. Chris A. Raanes President and CEO David Chandler Chief Financial Officer With extensive experience in the medical device field, Chris Raanes has held executive positions at companies such as Accuray and PerkinElmer Optoelectronics. As executive vice president and chief operating officer at Accuray, Raanes was instrumental in transforming the company from a start-up niche player into the number three vendor in the radiation therapy industry. He holds an MSEE from the Massachusetts Institute of Technology. Veteran CFO David Chandler has nearly three decades of experience in finance, strategic planning, mergers and acquisitions, investor relations, and accounting. Working with an array of businesses, Chandler has raised more than $100 million in private debt and equity capital, and $80 million in private M&A. James F. Dempsey, PhD Chief Scientific Officer Garth Nobis brings to ViewRay a proven track record in quality assurance and regulatory affairs. He has achieved a wide range of U.S. and international regulatory approvals, in addition to establishing robust quality systems for medical device companies such as Beckton Dickenson, Guidant, and several start-ups. Nobis holds an MBA from the University of Dayton. MRIdian’s design specifically enables the treatment of organs that are likely to move significantly during therapy, as lung tumors move when patients breathe. The ability to see soft tissue and adjust to its motion in real time can help assure clinicians that they are delivering the intended dose of radiation and avoiding normal tissues and critical structures, such as the spinal cord. In addition to lung cancer, ViewRay’s technology may be beneficial with tumors in head and neck, prostate, breast, bladder, and other types of cancer where tumor and organ motion can affect treatments. MRI is the clinically preferred method of imaging soft tissue. MRI technology (above left), can give clinicians a clearer view of the patient’s internal organs, such as the prostate, without delivering the extra ionizing radiation of computed tomography, or CT (above right). Company founder and inventor of the ViewRay technology, James Dempsey guides the scientific and technical aspects of the MRIdian system’s development. Dempsey holds a PhD in nuclear chemistry from Washington University. He is a board-certified medical physicist and former associate professor of radiation oncology at the University of Florida. Prabhakar Tripuraneni, MD, FACR, FASTRO About ViewRay Chief Medical Officer A privately held medical device company, ViewRay Incorporated holds the exclusive worldwide license for its patented combination of MRI and radiation therapy technologies. Early adopters of the MRIdian system include the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, Missouri; the University of Wisconsin Carbone Cancer Center; and the University of California, Los Angeles, Health System—Jonsson Comprehensive Cancer Center. Currently the head of radiation oncology at Scripps Green Hospital in La Jolla, California, Prabhakar Tripuraneni is a pioneer in coronary vascular brachytherapy. A graduate of Guntur Medical College in South India, he is the former president of ASTRO, the American Society for Therapeutic Radiology and Oncology. To learn more about ViewRay products and partnerships, contact your local ViewRay representative. ViewRay Incorporated 2 Thermo Fisher Way Oakwood Village, OH 44146 +1 440 703 3210 www.viewray.com © 2014 ViewRay Incorporated. All rights reserved. ViewRay and MRIdian are trademarks of ViewRay Incorporated. The names of other companies and products mentioned herein are used for identification purposes only and may be trademarks or registered trademarks of their respective owners. Rx ONLY L-0002 Rev. G 08/2014 Garth M. Nobis Vice President of Regulatory Affairs and Quality Assurance Michael Brandt Senior Vice President of Sales A veteran of the radiation therapy and medical imaging industries, Michael Brandt leads ViewRay’s worldwide sales and marketing programs. Prior to joining ViewRay, Brandt served as general manager of Accuray’s Americas and Europe, Middle East, India, and Africa (EMEIA) divisions, and held a series of international management positions at Philips Medical Systems. Stephen J. Strunk Vice President of Manufacturing An operations expert, Stephen Strunk specializes in the development and manufacturing of complex technologies. With more than two decades of experience in the medical device and high-tech industries, Strunk has held executive positions at companies such as Accuray, PerkinElmer, and Teledyne Dalsa.